Skip to main content
. 2023 May 6;55(4):661–671. doi: 10.3724/abbs.2023076

Figure 4 .


Figure 4

High RNF8 expression was associated with poor therapeutic benefits of sorafenib in HCC patients

HCC patients treated with sorafenib were stratified into subgroups according to RNF8 levels and subjected to Kaplan‒Meier survival analysis. (A) OS, overall survival. (B) PFS, progression-free survival. (C) RFS, relapse-free survival. (D) DSS, disease-free survival. P<0.05 was considered statistically significant.